NASDAQ:LPCN Lipocine Q4 2024 Earnings Results & Report $1.68 +0.06 (+3.40%) As of 02:32 PM Eastern This is a fair market value price provided by Massive. Learn more. Lipocine met analyst earnings expectations and missed on revenue in its Q4 2024 results, released May 8, 2025. The company reported EPS of -$0.35 versus the -$0.35 consensus estimate, while revenue of $0.09 million fell short of the $0.35 million estimate by $0.26 million. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ4 2024Report DateMay 8, 2025TimeBefore Market Opens Lipocine EPS ResultsActual EPS-$0.35Consensus EPS -$0.35Beat/MissMet ExpectationsOne Year Ago EPSN/AEPS Beat Rate3 of last 8 quartersLipocine Revenue ResultsActual Revenue$0.09 millionExpected Revenue$0.35 millionBeat/MissMissed by -$258.00 thousandYoY Revenue GrowthN/AUpcoming EarningsLipocine's Q3 2026 earnings is estimated for Thursday, November 5, 2026, based on past reporting schedules, with a conference call scheduled on Friday, November 6, 2026 at 9:30 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesEarnings HistoryCompany Profile Lipocine Q4 2024 Earnings FAQ Did Lipocine beat earnings estimates for Q4 2024? Lipocine (NASDAQ:LPCN) reported earnings of -$0.35 per share for Q4 2024, matching the consensus estimate of -$0.35. The report was announced on Thursday, May 8, 2025. What was Lipocine's revenue for Q4 2024? Lipocine reported revenue of $0.09 million for Q4 2024, against a consensus estimate of $0.35 million. When is Lipocine's next earnings date? Lipocine's next earnings date is estimated for Thursday, November 5, 2026. MarketBeat tracks confirmed and estimated earnings dates for Lipocine on the company's earnings history page. Lipocine Earnings HeadlinesLipocine (NASDAQ: LPCN) wins Health Canada approval for TLANDO in CanadaOctober 9, 2026 | americanbankingnews.comLipocine Announces Health Canada Approval of TLANDO(R) for Testosterone Replacement TherapyOctober 8, 2026 | marketscreener.comMMicroscopic footage reveals immune cells destroying cancer cellsTime-lapse footage from a recent clinical study shows Natural Killer cells attacking and eliminating cancer cells - and early human data revealed up to a 63.7 percent reduction in cancer burden. One NASDAQ-listed biotech's TriKE platform is designed to keep these immune cells locked onto tumors longer. Its next-generation version, showing potential for 10 to 40 times greater potency, has just cleared an important FDA milestone.October 14 at 1:00 AM | Market Tactic (Ad)Lipocine Announces Health Canada Approval of TLANDO for Testosterone Replacement TherapyOctober 8, 2026 | marketscreener.comMLipocine stock surges 30% on Health Canada drug approvalOctober 8, 2026 | finance.yahoo.com3 Penny Stocks to Watch Today, October 8October 8, 2026 | tipranks.comSee More Lipocine Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Lipocine? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Lipocine and other key companies, straight to your email. Email Address About LipocineLipocine (NASDAQ:LPCN) is a clinical-stage biopharmaceutical company focused on developing oral therapies for conditions with significant unmet medical needs. The company uses its proprietary Lip’ral drug-delivery technology to improve the absorption and administration of poorly bioavailable compounds, with the goal of offering alternatives to injectable or otherwise inconvenient treatments. Lipocine’s development programs have included oral hormone-replacement therapies, treatments for central nervous system disorders, and therapies for metabolic and liver-related conditions. Its lead product, TLANDO (testosterone undecanoate), was approved by the U.S. Food and Drug Administration in 2022 as an oral testosterone-replacement therapy for adult males with conditions associated with a deficiency or absence of endogenous testosterone. Based in Salt Lake City, Utah, Lipocine has historically focused primarily on the U.S. pharmaceutical market while advancing its pipeline through clinical development and commercial partnerships. The company is led by Mahesh Karande, who has served as its president and chief executive officer. Lipocine continues to evaluate and develop additional candidates based on its oral drug-delivery platform.View Lipocine ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Citi Stock Falls Despite Earnings Beat: What Investors Need to KnowDon’t Get NVIDIA’s Reflection AI Interest Wrong: Its Moat Could DeepenIREN Limited's AI Pivot Gains Traction—But Can Its Data Centers Deliver?PBF Energy's Stunning Rally Faces a Critical TestA Chinese Rival Just Spooked Memory Stocks—How Worried Should Micron Investors Be?Albertsons Is Betting on a Turnaround—But Will It Pay Off?PepsiCo's Earnings Beat Masks a Bigger Problem With Its North American Business Upcoming Earnings Interactive Brokers Group (10/15/2026)Marsh & McLennan Companies (10/15/2026)The PNC Financial Services Group (10/15/2026)Charles Schwab (10/15/2026)U.S. Bancorp (10/15/2026)Prologis (10/15/2026)Taiwan Semiconductor Manufacturing (10/15/2026)Truist Financial (10/16/2026)Travelers Companies (10/16/2026)HDFC Bank (10/17/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
